Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nafamostat Mesylate in Sepsis-Induced Coagulopathy
NCT06994312Not yet recruiting
- Sponsor
- The First Hospital of Jilin University
- Start
- Jul 2025
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
Randomised trial of Nafabelltan in sepsis-induced coagulopathy (SIC) (2 arms), sponsored by The First Hospital of Jilin University. Primary endpoint: ICU Mortality Rates at 1 year. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
Nafabelltan
03
Conditions
sepsis-induced coagulopathy (SIC)
Beyond the preview
Go deeper on NCT06994312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994312.